Join

Compare · CI vs DMTK

CI vs DMTK

Side-by-side comparison of The Cigna Group (CI) and DermTech Inc. (DMTK): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CI and DMTK operate in Medical Specialities (Health Care), so they compete in similar markets.
  • CI is the larger of the two at $77.37B, about 232.9x DMTK ($332.2M).
  • CI has hit the wire 14 times in the past 4 weeks while DMTK has been quiet.
  • CI has more recent analyst coverage (25 ratings vs 5 for DMTK).
MetricCIDMTK
Company
The Cigna Group
DermTech Inc.
Price
$275.55-1.49%
$0.10-11.65%
Market cap
$77.37B
$332.2M
1M return
+1.90%
-
1Y return
-17.71%
-
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2017
News (4w)
14
0
Recent ratings
25
5
CI

The Cigna Group

Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

DMTK

DermTech Inc.

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Latest CI

Latest DMTK